Drug Search Results
More Filters [+]

Admilparant

Alternative Names: Admilparant, bms-986278, bms986278, bms 986278
Latest Update: 2024-12-18
Latest Update Note: Clinical Trial Update

Product Description

Bristol-Myers Squibb is developing bms-986278, an Oral LPA1 Antagonist for Lung fibrosis

Mechanisms of Action: LPA1 Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: Breakthrough Therapy - Pulmonary Fibrosis|Progressive Pulmonary Fibrosis *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Admilparant

Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, India, Ireland, Israel, Italy, Japan, Korea, Mexico, Netherlands, Peru, Poland, Portugal, Puerto Rico, Spain, Sweden, Switzerland, Taiwan, Turkey, United Kingdom, United States, Unknown Location

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Idiopathic Pulmonary Fibrosis|Progressive Pulmonary Fibrosis

Phase 2: Pulmonary Fibrosis

Phase 1: Healthy Volunteers|Kidney Failure, Chronic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

IM027-1015

P3

Recruiting

Progressive Pulmonary Fibrosis

2027-12-27

jRCT2021230026

P3

Recruiting

Idiopathic Pulmonary Fibrosis

2027-12-03

jRCT2021230037

P3

Recruiting

Progressive Pulmonary Fibrosis

2027-09-02

IM027-068

P3

Recruiting

Idiopathic Pulmonary Fibrosis

2026-10-26

Recent News Events